MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial-Reference-Cited by-同舟云学术

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial

Published:2020-04-07 Issue:3 Volume:108 Page:596-605
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Okuma Hitomi S.¹^ORCID,Yonemori Kan²,Narita Shoko N.³,Sukigara Tamie³,Hirakawa Akihiro⁴,Shimizu Toshio⁵,Shibata Taro⁶,Kawai Akira⁷,Yamamoto Noboru⁸,Nakamura Kenichi³,Nishida Toshiro⁹,Fujiwara Yasuhiro¹⁰

Affiliation:

1. Department of Breast and Medical Oncology Clinical Research Support Office National Cancer Center Hospital Tokyo Japan

2. Department of Breast and Medical Oncology Rare Cancer Center National Cancer Center Hospital Tokyo Japan

3. Clinical Research Support Office National Cancer Center Hospital Tokyo Japan

4. Department of Biostatistics and Bioinformatics Graduate School of Medicine The University of Tokyo Tokyo Japan

5. Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan

6. Biostatistics Division, Center for Research Administration and Support National Cancer Center Tokyo Japan

7. Department of Musculoskeletal Oncology Rare Cancer Center National Cancer Center Hospital Tokyo Japan

8. Department of Experimental Therapeutics Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

9. Department of Surgery National Cancer Center Hospital Tokyo Japan

10. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

Funder

Otsuka Pharmaceutical

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1817

Reference17 articles.

1. National Cancer Institute: Molecular Analysis for Therapy Choice (NCIMATCH. Accessed July 31 2019.

2. Regulatory Review of New Therapeutic Agents

3. The notorious “drug lag” for oncology drugs in Japan

4. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers

5. Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer registry as external control data for regulatory submission in Japan;ESMO Real World Data and Digital Oncology;2024-12

2. Identification of barriers to implementation of precision oncology in patients with rare cancers;Cancer Science;2024-03-27

3. Global Equity in Clinical Trials: An ASCO Policy Statement;JCO Global Oncology;2024-03

4. Considerations for master protocols using external controls;Journal of Biopharmaceutical Statistics;2024-02-16

5. Challenges and opportunities in rare cancer research in China;Science China Life Sciences;2023-11-23